SEC Tracker
Get the app

Perspective Therapeutics CATX

Perspective Therapeutics reports 3Q 2026 results

Perspective Therapeutics (CATX) filed an 8-K with the SEC on Nov 9, 2026, 4:33 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results, Item 8.01 Other events

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and short-term investments were $202 million as of September 30, 2026.
  2. Net loss for the three months ended September 30, 2026, was $32.4 million.
  3. Research and development expenses were $26.1 million for the three months ended September 30, 2026.
  4. PSV359 received Fast Track Designation from the FDA for FAP-positive solitary fibrous tumors.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Perspective Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.